美国扩大年龄为基础丙型肝炎检测推荐的人群水平结局与成本效果
该研究利用丙型肝炎病毒(HCV)模拟模型,评估将一次性HCV检测推荐扩大至≥40岁、≥30岁和≥18岁人群(所有策略均假设对高危人群进行针对性检测)相较于标准治疗(1945-1965年出生人群一次性检测)的效果与成本效果。扩大年龄为基础检测策略提高了美国人群终生病例识别率和治愈率,以≥18岁策略增幅最大。与标准治疗相比,≥18岁策略估计额外识别256,000例感染者并额外治愈280,000例,每获得一个质量调整生命年的增量成本效果比(ICER)为28,000美元/QALY。作者认为对18岁及以上人群进行一次性HCV检测似乎具有成本效果,可考虑用于未来推荐修订。
要点
- 扩大年龄为基础HCV检测策略可提高美国人群终生病例识别率和治愈率。
- ≥18岁策略较标准治疗估计额外识别256,000例感染者、额外治愈280,000例。
- ≥18岁策略ICER为28,000美元/QALY,作者认为对≥18岁人群一次性检测似乎具有成本效果。
核心结论
- 除风险为基础检测外,对18岁及以上人群进行一次性HCV检测似乎具有成本效果,可改善临床结局并较当前出生队列推荐识别更多HCV感染者;这些发现可考虑用于未来推荐修订。
研究设计与样本
- 研究使用HCV模拟模型估计四种检测策略的效果与成本效果:标准治疗(推荐1945-1965年出生者一次性检测)、推荐≥40岁成人一次性检测(≥40策略)、≥30岁(≥30策略)、≥18岁(≥18策略);所有策略均假设对高危人群进行针对性检测;输入数据来源于国家数据库、观察性队列和临床试验。
主要发现
- 扩大年龄为基础检测策略提高了美国人群终生病例识别率和治愈率,其中≥18策略增幅最大。
- 与标准治疗相比,≥18策略估计额外识别256,000例感染者并额外治愈280,000例,ICER为28,000美元/QALY。
关键数值与推荐
- 美国疾病控制与预防中心和美国预防服务工作组推荐对1945-1965年出生者进行一次性HCV检测,并对高危人群进行针对性检测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born 1945-1965 and targeted testing for high-risk persons. This strategy targets HCV testing to a prevalent population at high risk for HCV morbidity and mortality, but does not include younger populations with high incidence. To address this gap and improve access to HCV testing, age-based strategies should be considered. METHODS: We used a simulation of HCV to estimate the effectiveness and cost-effectiveness of HCV testing strategies: 1) standard of care (SOC) - recommendation for one-time testing for all persons born 1945-1965, 2) recommendation for one-time testing for adults ≥40 years (≥40 strategy), 3) ≥30 years (≥30 strategy), and 4) ≥18 years (≥18 strategy). All strategies assumed targeted testing of high-risk persons. Inputs were derived from national databases, observational cohorts and clinical trials. Outcomes included quality-adjusted life expectancy, costs, and cost-effectiveness. RESULTS: Expanded age-based testing strategies increased US population lifetime case identification and cure rates. Greatest increases were observed in the ≥18 strategy. Compared to the SOC, this strategy resulted in an estimated 256,000 additional infected persons identified and 280,000 additional cures at the lowest cost per QALY gained (ICER = $28,000/QALY). CONCLUSIONS: In addition to risk-based testing, one-time HCV testing of persons 18 and older appears to be cost-effective, leads to improved clinical outcomes and identifies more persons with HCV than the current birth cohort recommendations. These findings could be considered for future recommendation revisions.
引用
- Barocas JA, Tasillo A, Eftekhari Yazdi G, et al. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clin Infect Dis. 2018. PMID: 29420742. doi:10.1093/cid/ciy098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。